88 related articles for article (PubMed ID: 32940815)
61. Identification and validation of novel circulating biomarkers for early diagnosis of lung cancer.
Zhang L; Pu D; Liu D; Wang Y; Luo W; Tang H; Huang Y; Li W
Lung Cancer; 2019 Sep; 135():130-137. PubMed ID: 31446985
[TBL] [Abstract][Full Text] [Related]
62. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
63. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
Shinke H; Masuda S; Togashi Y; Ikemi Y; Ozawa A; Sato T; Kim YH; Mishima M; Ichimura T; Bonventre JV; Matsubara K
Cancer Chemother Pharmacol; 2015 Nov; 76(5):989-96. PubMed ID: 26407820
[TBL] [Abstract][Full Text] [Related]
64. Potential circulating miRNA signature for early detection of NSCLC.
Arab A; Karimipoor M; Irani S; Kiani A; Zeinali S; Tafsiri E; Sheikhy K
Cancer Genet; 2017 Oct; 216-217():150-158. PubMed ID: 29025589
[TBL] [Abstract][Full Text] [Related]
65. Urinary mRNA biomarker panel for the detection of urothelial carcinoma.
Urquidi V; Netherton M; Gomes-Giacoia E; Serie D; Eckel-Passow J; Rosser CJ; Goodison S
Oncotarget; 2016 Jun; 7(25):38731-38740. PubMed ID: 27231851
[TBL] [Abstract][Full Text] [Related]
66. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
[TBL] [Abstract][Full Text] [Related]
67. High-performance liquid chromatographic method for the determination of p-aminobenzoic acid and some of its metabolites.
Brown ND; Lofberg TR; Gibson TP
J Chromatogr; 1974 Nov; 99(0):635-41. PubMed ID: 4417450
[No Abstract] [Full Text] [Related]
68. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
69. Clinical significance of urinary plasminogen and fibrinogen gamma chain as novel potential diagnostic markers for non-small-cell lung cancer.
Zhang W; Gao Z; Zeng G; Xie H; Liu J; Liu N; Wang G
Clin Chim Acta; 2020 Mar; 502():55-65. PubMed ID: 31821791
[TBL] [Abstract][Full Text] [Related]
70. Urinary metabolite and lipid alterations in Colombian Hispanic women with breast cancer: A pilot study.
Cala M; Aldana J; Sánchez J; Guio J; Meesters RJW
J Pharm Biomed Anal; 2018 Apr; 152():234-241. PubMed ID: 29428809
[TBL] [Abstract][Full Text] [Related]
71. The impact of the lung EDRN-CVC on Phase 1, 2, & 3 biomarker validation studies.
Kammer MN; Deppen SA; Antic S; Jamshedur Rahman SM; Eisenberg R; Maldonado F; Aldrich MC; Sandler KL; Landman B; Massion PP; Grogan EL
Cancer Biomark; 2022; 33(4):449-465. PubMed ID: 35491773
[TBL] [Abstract][Full Text] [Related]
72. Polyurea-Modified Magnetic Particles with Versatile Probes for Chemoselective Capture of Carbonyl Metabolites and Biomarker Discovery.
Zhang M; Lai Z; Zhang R; Liu S; Tian H; Qiu Y; Li D; Zhou J; Li Z
Small; 2023 Jan; 19(1):e2204734. PubMed ID: 36354199
[TBL] [Abstract][Full Text] [Related]
73. Metabolic biomarkers in lung cancer screening and early diagnosis (Review).
Xu Y; Dong X; Qin C; Wang F; Cao W; Li J; Yu Y; Zhao L; Tan F; Chen W; Li N; He J
Oncol Lett; 2023 Jun; 25(6):265. PubMed ID: 37216157
[TBL] [Abstract][Full Text] [Related]
74. Acyl-CoA Binding Domain Containing 4 Polymorphism rs4986172 and Expression Can Serve as Overall Survival Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Hepatectomy.
Huang H; Liao X; Zhu G; Han C; Wang X; Yang C; Zhou X; Liang T; Huang K; Peng T
Pharmgenomics Pers Med; 2022; 15():277-300. PubMed ID: 35378899
[TBL] [Abstract][Full Text] [Related]
75. Strong Dependence between Tryptophan-Related Fluorescence of Urine and Malignant Melanoma.
Birková A; Valko-Rokytovská M; Hubková B; Zábavníková M; Mareková M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668679
[TBL] [Abstract][Full Text] [Related]
76. Urinary fluorescent metabolite O-aminohippuric acid is a useful biomarker for lung cancer detection.
Funai K; Honzawa K; Suzuki M; Momiki S; Asai K; Kasamatsu N; Kawase A; Shinke T; Okada H; Nishizawa S; Takamoto H
Metabolomics; 2020 Sep; 16(10):101. PubMed ID: 32940815
[TBL] [Abstract][Full Text] [Related]
77. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
78. Urine cell-free DNA as a promising biomarker for early detection of non-small cell lung cancer.
Ren S; Ren XD; Guo LF; Qu XM; Shang MY; Dai XT; Huang Q
J Clin Lab Anal; 2020 Aug; 34(8):e23321. PubMed ID: 32281142
[TBL] [Abstract][Full Text] [Related]
79. Serum lipidomic biomarkers for non-small cell lung cancer in nonsmoking female patients.
Noreldeen HAA; Du L; Li W; Liu X; Wang Y; Xu G
J Pharm Biomed Anal; 2020 Jun; 185():113220. PubMed ID: 32145537
[TBL] [Abstract][Full Text] [Related]
80. Serum mass profile signature as a biomarker of early lung cancer.
Widlak P; Pietrowska M; Polanska J; Marczyk M; Ros-Mazurczyk M; Dziadziuszko R; Jassem J; Rzyman W
Lung Cancer; 2016 Sep; 99():46-52. PubMed ID: 27565913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
